Alexion Pharmaceuticals, Inc. (ALXN) Grows Revenues Above 40% with Wonder Drug Soliris

May 27, 2014

Managing Director Diane Wehner of Teton Advisors says Alexion Pharmaceuticals, Inc. (ALXN) is a high-growth company with proprietary technology that’s been growing its revenues above 40% for the last five years.

“[Alexion is] a biotech company with sales of $1.5 billion in 2013,” Wehner said. “They generate revenues from a commercialized drug called Soliris, which is an antibody drug that treats rare diseases. This is the focus of the company…Soliris is literally a wonder drug that saves patients’ lives.”

FOR MORE INFORMATION ON THIS INTERVIEW CLICK HERE.

As a result, Alexion has huge barriers to entry and competitive advantages, Wehner says. The company has also acquired other drugs in the orphan disease space, opening up further opportunities.

“The company has taken the profits generated from Soliris and they’ve acquired additional drugs that target rare diseases creating a pipeline of opportunities for the next several years…The portfolio has benefited from owning the stock over the last five years, which has appreciated over 771%. It’s been an enormous investment for us,” Wehner said.